(COYA)
NCM – Real vaqt narxi. Valyuta: USD
3.96
-0.22 (-5.26%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.04
+0.08 (2.02%)
Bozordan keyin: Mar 27, 2026, 5:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
3.96
-0.22 (-5.26%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.04
+0.08 (2.02%)
Bozordan keyin: Mar 27, 2026, 5:00 PM EDT
Coya Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, regulyator T hujayralarining (Tregs) funktsiyasini yaxshilash uchun patentlangan terapiyalarni ishlab chiqadi. Kompaniyaning mahsulot nomzodlari quvur liniyasi Tregni kuchaytiruvchi biologik vositalar, Tregdan olingan ekzosomalar va avtolog Treg hujayra terapiyasi kabi terapevtik modalitlarga asoslangan. U amiotrofik lateral skleroz, shuningdek, frontotemporal demensiya, Altsgeymer kasalligi (AD) va Parkinson kasalligini davolash uchun 2-bosqichli sinovda Treg funktsiyasini oshirish, shu bilan birga T-effektor funktsiyasi va faollashgan makrofaglarni kamaytirishga mo'ljallangan teri ostiga yuboriladigan biologik kombinatsiyasi COYA 302ni ishlab chiqadi. Bundan tashqari, kompaniyaning preklinik mahsulot nomzodlari orasida ADni davolash uchun past dozali interleukin 2 nomzodi COYA 301; yallig'lanish kasalliklarini davolash uchun COYA 301 va glyukagon-o'xshash peptid-1 retseptor agonisti investigatsiyaviy biologik kombinatsiyasi COYA 303; neyrodegenerativ, otoimmün va metabolik kasalliklarni davolash uchun antigen yo'naltirilgan Tregdan olingan ekzom nomi COYA 201; antigen yo'naltirilgan Tregdan olingan ekzom nomi COYA 206; va COYA 101 mavjud. U amiotrofik lateral sklerozni davolash uchun investigatsiyaviy kombinatsiyalangan terapiya COYA 302ni ishlab chiqish va tijoratlashtirish bo'yicha Dr. Reddy's Laboratories SA bilan hamkorlik qiladi. Coya Therapeutics, Inc. 2020 yilda tashkil etilgan va Xyuston, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Arun Swaminathan Ph.D. | CEO & Director |
| Dr. Fred Grossman D.O., FAPA | President & Chief Medical Officer |
| Dr. Howard H. Berman Ph.D. | Co-Founder & Executive Chair |
| Dr. Michelle Frazier Ph.D. | Senior Vice President of Regulatory |
| Mr. Aaron Thome Ph.D. | Head of Neuroinflammation Platform |
| Mr. David S. Snyder M.B.A. | CFO & COO |
| Ms. Karen King M.S. | Senior VP of Program Management & Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-16 | 8-K | coya-20260316.htm |
| 2026-01-30 | 8-K | d88735d8k.htm |
| 2026-01-20 | 8-K | d48170d8k.htm |
| 2026-01-08 | 8-K | d39008d8k.htm |
| 2025-12-17 | 8-K | d729078d8k.htm |
| 2025-11-12 | 10-Q | coya-20250930.htm |
| 2025-09-02 | 8-K | d95745d8k.htm |
| 2025-08-18 | CORRESP | filename1.htm |
| 2025-08-12 | 8-K | coya-20250812.htm |
| 2025-07-29 | 8-K | d14950d8k.htm |